[Galantamine therapy in dementia associated with CADASIL]

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencefalopathy (CADASIL) is a genetic condition affecting small blood vessels in the brain.
• Cholinergic neuronal pathways are implicated in cognitive function and may be impaired in CADASIL.
• Cholinomimetic agents, such as acetylcholinesterase inhibitors, are potential therapeutic options.

Observation:

• Four patients diagnosed with CADASIL and exhibiting dementia were enrolled in the study.
• The treatment administered was galantamine, an acetylcholinesterase inhibitor.
• Assessments included cognitive, behavioral, functional outcomes, and caregiver burden.

Findings:

• Three out of the four patients demonstrated either mild cognitive improvement or stabilization of behavioral symptoms and reduced caregiver burden.
• No significant adverse events were reported, suggesting a favorable safety profile for galantamine in this cohort.
• The observed improvements, though modest, indicate a potential positive response to acetylcholinesterase inhibition.

Implications:

• The findings suggest that a cholinergic deficit may contribute to cognitive impairment in CADASIL.
• Galantamine treatment showed promising results, supporting its potential as a therapeutic option for managing dementia in CADASIL patients.
• Further research with larger sample sizes is warranted to confirm these preliminary findings and elucidate the role of cholinergic systems in CADASIL pathogenesis.